Τόμος 23 (2009) – Τεύχος 2 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 23 (2009) – Issue 2 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

A’ Department of Pharmacology, Medical School, Aristotle University of Thessaloniki, Greece

pharmakonpress[at]pharmakonpress[.]gr

2. Guyton A., Hall J.: Textbook of Medical Physiology. 11^th ed., Saunders, Philadelphia, 2006

3. Maggioni A.P.: Efficacy of Angiotensin receptor blockers in cardiovascular disease. Cardiovasc. Drugs Ther. 20: 295-308 (2006)

4. Unger T., Stoppelhaar M.: Rationale for double reninangiotensin-aldosterone system blockade. Am. J. Cardiol. 100(3A): 25J-31J (2007)

5. Westermann D., Schmieder R., Schultheiss H.P.,Tschöpe C.: Renin inhibitors, clinical experience. J. Mol. Med. 86: 691-5 (2008)

6. Danser A.H.: Novel drugs targeting hypertension: renin inhibitors. J. Cardiovasc. Pharmacol. 50: 105-111 (2007)

7. Triller D.M., Evang S.D., Tadrous M., Yoo B.K.: First renin inhibitor, aliskiren, for the treatment of hypertension. Pharm. World Sci. 30: 741-749 (2008)

8. Pool J.L.: Direct renin inhibition: focus on aliskiren. J. Manag. Care Pharm. 13(8 Suppl B): 21-33 (2007)

9. Gaddam K.K., Oparil S.: Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients? Curr. Opin. Nephrol. Hypertens. 17: 484-490 (2008)

10. Lam S., Choy M.: Aliskiren: an oral renin inhibitor for the treatment of hypertension. Cardiol. Rev. 15: 316-323 (2007)

11. Azizi M.: Direct renin inhibition: clinical pharmacology. J. Mol. Med. 86: 647-654 (2008)

12. Panagopoulos P.K., Triantafyllou G.A., Mironidou-Tzouveleki M.: Angiotensin converting enzyme inhibitors, angiotensin receptor blockers and the effectiveness of their combination. Rev. Clin. Pharmacol. Pharmacokinet., Int. Ed., 22: 431-438 (2008)

13. Müller D.N., Luft F.C.: Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin. J. Am. Soc. Nephrol. 1: 221-228 (2006)

14. Shafiq M.M., Menon D.V., Victor R.G.: Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am. J. Med. 121: 265-271 (2008)

15. Sepehrdad R., Frishman W.H., Stier C.T. Jr, Sica D.A.: Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. Cardiol. Rev. 15: 242-56 (2007)

16. McMurray J.J.V., Pitt B., Latini R., Maggioni A.P., Solomon S.D., Keefe D.L., Ford J., Verma A., Lewse J.; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1: 17–24 (2008)

17. Gradman A.H., Pinto R., Kad R.: Current concepts: renin inhibition in the treatment of hypertension. Curr. Opin. Pharmacol. 8: 120-126 (2008)

18. Weir M.R.: Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? Curr. Opin. Nephrol. Hypertens. 16: 416-421 (2007)

19. Verdecchia P., Angeli F., Mazzotta G., Gentile G., Reboldi G.: The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc. Health Risk. Manag. 4: 971-981 (2008)

20. Gradman A.H., Kad R.: Renin inhibition in hypertension. J. Am. Coll. Cardiol. 51: 519-528 (2008)

21. Villamil A., Chrysant S.G., Calhoun D., Schober B., Hsu H., Matrisciano-Dimichino L., Zhang J.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. 25: 217-226 (2007)

22. Pool J.L., Schmieder R.E., Azizi M., Aldigier J.C., Januszewicz A., Zidek W., Chiang Y., Satlin A.: Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am. J. Hypertens. 20: 11-20 (2007)

23. Oparil S., Yarows S.A., Patel S., Fang H., Zhang J., Satlin A.: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 370: 221-229 (2007)

24. Uresin Y., Taylor A., Kilo C., Tschöpe D., Santonastaso M., Ibram G., Fang H., Satlin A.: Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J. Hypertens. 24(Suppl 4): 82 (2006)

25. Solomon S.D., Appelbaum E., Manning W.J., Verma A., Berglund T., Lukashevich V., Cherif Papst C., Smith B.A., Dahlöf B.: Aliskiren in left ventricular hypertrophy (ALLAY) Trial Investigators: Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 119: 530-537 (2009)

26. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K.; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358: 2433-2446 (2008)

27. Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D., Haffner S.M., Solomon S.D., Chaturvedi N., Ghadanfar M., Weissbach N., Xiang Z., Armbrecht J., Pfeffer M.A.: Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24: 1663-1671 (2009)

28. Schefe J.H., Unger T., Funke-Kaiser H.: PLZF and the (pro)renin receptor. J. Mol. Med. 86: 623-627 (2008)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr